文献速递妇科

巨细胞病毒与全身炎症同手术时不良结局相关

Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-11-07

该研究纳入2006至2009年106例浆液性卵巢癌患者,术前检测CMV IgG与CRP并分组比较生存。CMV+/CRP+组无复发生存和总生存显著差于CMV-/CRP-组,而CMV+/CRP-组总生存最长。

要点

  • CMV+/CRP+组RFS为16.9个月,OS为31.7个月。
  • CMV+/CRP-组总生存最长,达89.3个月。
  • CRP升高者CA-125更高且减灭不满意率更高。

核心结论

  • 既往CMV暴露合并手术时CRP升高与浆液性卵巢癌更差的无复发生存和总生存相关。
  • 无炎症时单纯CMV阳性组总生存最长,提示CMV状态可能具保护作用。

研究设计与样本

  • 回顾性分析2006至2009年106例浆液性卵巢癌患者术前血清CMV IgG与CRP。
  • 按CMV IgG(非反应性、反应性/临界)和CRP(≤10、>10 mg/L)分层比较生存。

主要发现

  • 106例中CMV+/CRP+ 40例(37.7%),CMV+/CRP- 24例(22.6%),CMV-/CRP+ 19例(17.9%),CMV-/CRP- 23例(21.7%)。
  • CRP+者CA-125水平更高(P=0.05),减灭不满意率更高(P=0.03)。
  • CMV+/CRP+组中位RFS 16.9个月(95%CI 9.0-21.1),中位OS 31.7个月(95%CI 25.0-48.7)。
  • CMV-/CRP-组中位RFS 31.2个月(95%CI 16.0-56.4),中位OS 63.8个月(95%CI 50.7-87.0)。
  • CMV+/CRP-组总生存最长,达89.3个月。

关键数值与推荐

  • CMV+/CRP+对比CMV-/CRP-的RFS:aHR 1.85(95%CI 1.05-3.24,P=0.03)。
  • CMV+/CRP+对比CMV-/CRP-的OS:aHR 2.12(95%CI 1.17-3.82,P=0.01)。
  • 分组阈值:CMV IgG非反应性/反应性或临界;CRP≤10或>10 mg/L。

临床怎么用

  • 术前可结合CMV IgG与CRP分层评估浆液性卵巢癌预后风险。
  • CMV+/CRP+患者可能需更密切随访或强化治疗策略。

局限性

  • 样本量较小(106例),仅纳入浆液性卵巢癌。
  • 为观察性研究,CMV与结局的因果关系不能确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cytomegalovirus (CMV) is a common infection that establishes latency in healthy people. CMV has been associated with alterations of the immune compartment leading to improved responses, while inflammation has been shown to adversely impact outcomes. We investigated whether CMV serostatus predicts outcomes in ovarian cancer in the presence or absence of inflammation. METHODS: A total of 106 patients with serous ovarian cancer from 2006 to 2009 were analyzed. CMV and systemic inflammation was measured using CMV immunoglobulin G (IgG) and C-reactive protein (CRP), respectively, in serum collected prior to cytoreduction. Patients were stratified by CMV IgG (non-reactive, reactive/borderline) and CRP (≤10, >10 mg/L) status. Overall survival (OS) and recurrence-free survival (RFS) were compared by group using log-rank tests and Cox proportional hazards regression models adjusting for age at surgery. RESULTS: Of 106 eligible patients, 40 (37.7%) were CMV+/CRP+, 24 (22.6%) CMV+/CRP-, 19 (17.9%) CMV-/CRP+, and 23 (21.7%) CMV-/CRP-. CRP+ had higher CA-125 levels (P = 0.05) and higher rates of suboptimal debulking (P = 0.03). There were no other significant differences in demographic, surgical, or pathologic factors between groups. CMV+/CRP+ patients median RFS and OS were 16.9 months (95% CI: 9.0-21.1) and 31.7 months (95% CI: 25.0-48.7), respectively, with a significantly worse RFS (aHR: 1.85, 95% CI: 1.05-3.24, P = 0.03) and OS (aHR: 2.12, 95% CI: 1.17-3.82, P = 0.01) compared to CMV-/CRP- (RFS = 31.2 months (95% CI: 16.0-56.4) and OS = 63.8 months (95% CI: 50.7-87.0)). CMV+/CRP- group displayed the longest OS (89.3 months). CONCLUSIONS: Previous exposure to CMV and high CRP at surgery portended worse RFS and OS compared to women who tested negative. The CMV+/CRP- group had the longest OS, indicating that CMV status alone, in the absence of inflammation, may be protective.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wesley E, Uppendahl LD, Felices M, et al. Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer. Gynecol Oncol. 2020. PMID: 33168306. doi:10.1016/j.ygyno.2020.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。